Novo Nordisk的股票下跌,尽管收入丰厚,Ozempic有新的潜力,并有购买评级。 Novo Nordisk's stock dips despite strong earnings, new potential for Ozempic, and buy ratings.

Novo Nordisk的股票最近出现下降,部分原因在于竞争对手的超级碗广告以及摩根斯坦利的“控股”评级。 Novo Nordisk's stock has seen recent declines, partly due to a rival's Super Bowl ad and a "hold" rating from Morgan Stanley. 然而,一项研究表明,其Ozempic产品可能为减少酒精和戒烟带来新的收入来源。 However, a study suggests its Ozempic product may have new revenue streams for alcohol reduction and smoking cessation. 尽管收入下降,但收入超过估计,机构投资者购买了更多的股票,并获得一致的“最佳购买”评级和增长潜力。 Despite the dips, earnings surpassed estimates, and institutional investors are buying more shares, with a consensus "Moderate Buy" rating and potential for growth.